These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23027029)

  • 21. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract]   [Full Text] [Related]  

  • 22. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract]   [Full Text] [Related]  

  • 23. Proceedings from the XIth International Symposium on Advances in Targeted Therapies, 22 to 26 April 2009.
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i1-99. PubMed ID: 20310079
    [No Abstract]   [Full Text] [Related]  

  • 24. The application of infliximab (Remicade), a chimeric monoclonal antibody, in the treatment of rheumatic diseases.
    Kalden JR
    Isr Med Assoc J; 2000 Dec; 2 Suppl():11-2. PubMed ID: 11344856
    [No Abstract]   [Full Text] [Related]  

  • 25. Anti-tumour necrosis factor agents and lipid profile: a class effect?
    Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
    Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
    [No Abstract]   [Full Text] [Related]  

  • 26. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
    Furst DE; Keystone EC; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Braun J; Bresnihan B; Burmester GR; De Benedetti F; Dörner T; Emery P; Gibofsky A; Kavanaugh A; Kirkham B; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH; Winthrop K
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i2-29. PubMed ID: 19995740
    [No Abstract]   [Full Text] [Related]  

  • 27. Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy.
    Winthrop KL; Furst DE
    Ann Rheum Dis; 2010 Oct; 69(10):1735-7. PubMed ID: 20858622
    [No Abstract]   [Full Text] [Related]  

  • 28. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
    Al-Mayouf SM; Alenazi A; AlJasser H
    Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy?
    Winger EE; Reed JL
    J Rheumatol; 2009 Sep; 36(9):2122; author reply 2123. PubMed ID: 19738224
    [No Abstract]   [Full Text] [Related]  

  • 30. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.
    Furst DE; Keystone EC; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop K
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i2-45. PubMed ID: 22460137
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis in Lebanon.
    Uthman I; Mroueh K; Arayssi T; Nasr F; Masri AF
    Semin Arthritis Rheum; 2004 Jun; 33(6):422-3. PubMed ID: 15260002
    [No Abstract]   [Full Text] [Related]  

  • 32. Biological agents and tuberculosis: risk estimates and screening strategies.
    Dobler CC
    Int J Rheum Dis; 2015 Mar; 18(3):264-7. PubMed ID: 25923605
    [No Abstract]   [Full Text] [Related]  

  • 33. Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases.
    Huvers FC; Popa C; Netea MG; van den Hoogen FH; Tack CJ
    Ann Rheum Dis; 2007 Apr; 66(4):558-9. PubMed ID: 17360784
    [No Abstract]   [Full Text] [Related]  

  • 34. Completion rate and compliance of anti-tuberculosis chemoprophylaxis in patients with rheumatic disease receiving tumor necrosis factor antagonists.
    Ideguchi H; Ohno S; Takase K; Kirino Y; Suda A; Ihata A; Ueda A; Takeno M; Nagaoka S; Ishigatsubo Y
    Clin Exp Rheumatol; 2010; 28(2):294-5. PubMed ID: 20483059
    [No Abstract]   [Full Text] [Related]  

  • 35. Setting the research agenda for future clinical trials on the use of biologics in rheumatology.
    Silman A; Rudkin S; Walley T
    Rheumatology (Oxford); 2011 Aug; 50(8):1356-7. PubMed ID: 21118870
    [No Abstract]   [Full Text] [Related]  

  • 36. Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?
    Wendling D; Di Martino V; Herbein G
    J Rheumatol; 2009 Jun; 36(6):1107-8. PubMed ID: 19509089
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of vaccination in rheumatic disease.
    Wong PKK; Hanrahan P
    Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):720-734. PubMed ID: 31427051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy: Are TNF blockers safe for patients with hepatitis B virus infection?
    Ramos-Casals M
    Nat Rev Rheumatol; 2010 Nov; 6(11):618-20. PubMed ID: 21037559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Varicella-zoster virus infection in rheumatoid arthritis patients in the anti-tumour necrosis factor era.
    Cacciapaglia F; Zuccaro C; Iannone F
    Clin Exp Rheumatol; 2015; 33(6):917-23. PubMed ID: 26394271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor necrosis factor-alpha blocker induced tuberculosis.
    Kharbanda P; Dagaonkar R; Balakrishnan C; Udwadia ZF
    J Rheumatol; 2010 Jul; 37(7):1542; author reply 1543. PubMed ID: 20595292
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.